- Trials with a EudraCT protocol (1,111)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
1,111 result(s) found for: Brain function.
Displaying page 7 of 56.
EudraCT Number: 2017-005029-19 | Sponsor Protocol Number: CV010031 | Start Date*: 2020-06-09 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarc... | ||||||||||||||||||
Medical condition: Ischemic Stroke or Transient Ischemic Attack (TIA) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) DE (Completed) ES (Ongoing) SE (Completed) HU (Completed) NO (Completed) FI (Completed) BE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DK (Completed) GR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000645-14 | Sponsor Protocol Number: EFC16035 | Start Date*: 2020-10-13 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) | |||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) BG (Trial now transitioned) EE (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) NO (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) LV (Completed) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007853-30 | Sponsor Protocol Number: sNN0031-001 | Start Date*: 2009-01-28 |
Sponsor Name:NeuroNova AB | ||
Full Title: A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate s... | ||
Medical condition: Idiopathic Parkinson's disease (PD) of moderate severity (modified Hoehn & Yahr Stage IIb - III) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004875-11 | Sponsor Protocol Number: CAMG334AIT03 | Start Date*: 2019-05-29 | |||||||||||
Sponsor Name:NOVARTIS FARMA S.P.A. | |||||||||||||
Full Title: A RandomizEd, double-blind, cross-over Study to assess Erenumab effecT on BRAIN networks function and structure in comparison to placebo in episodic migraine patients (RESET BRAIN) | |||||||||||||
Medical condition: Episodic migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006638-38 | Sponsor Protocol Number: 2021/3282 | Start Date*: 2022-05-18 |
Sponsor Name:GUSTAVE ROUSSY | ||
Full Title: A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors - VAPOR (GETUG T06) | ||
Medical condition: Non-seminomatous germ-cell tumors (including testis, retroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified ... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001087-10 | Sponsor Protocol Number: ELA-0121 | Start Date*: 2022-11-21 | |||||||||||
Sponsor Name:Stemline Therapeutics, Inc | |||||||||||||
Full Title: An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative B... | |||||||||||||
Medical condition: Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006042-32 | Sponsor Protocol Number: GE-067-019 | Start Date*: 2012-09-12 | |||||||||||
Sponsor Name:GE Healthcare Ltd and its affiliates | |||||||||||||
Full Title: A Single-Arm Open-Label Multi-Center Study to Determine the Test-Retest Variability of PET Brain Imaging with Flutemetamol (18F) Injection. | |||||||||||||
Medical condition: Subjects with amnestic Mild Cognitive Impairment (aMCI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004753-14 | Sponsor Protocol Number: 109MS303 | Start Date*: 2009-01-22 | |||||||||||
Sponsor Name:Biogen Idec Limited | |||||||||||||
Full Title: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) SK (Completed) DE (Completed) IE (Completed) LV (Completed) ES (Completed) FR (Completed) EE (Completed) GR (Completed) AT (Completed) NL (Completed) BG (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004170-25 | Sponsor Protocol Number: MH-110 | Start Date*: Information not available in EudraCT |
Sponsor Name:Bracco Imaging S.p.A. | ||
Full Title: A PHASE III, MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE SAFETY AND EFFICACY OF MULTIHANCE® AT THE DOSE OF 0.10 mmol/kg IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC PA... | ||
Medical condition: imaging diagnosis of highly suspected or known brain and/or spine disease, which are known to impair the Blood Brain Barrier Function | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001724-19 | Sponsor Protocol Number: 2013/2 | Start Date*: 2014-05-13 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | |||||||||||||
Full Title: Pilot study to assess P-glycoprotein function at the blood-brain barrier of patients with mild to moderate Alzheimer's disease | |||||||||||||
Medical condition: Alzheimer's disease and healthy controls (2 groups: 1 group with young healthy volunteers, 1 group with elderly healthy volunteers) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000096-32 | Sponsor Protocol Number: METRO-PD1-1708 | Start Date*: 2018-11-15 | ||||||||||||||||||||||||||
Sponsor Name:Centre Oscar Lambret | ||||||||||||||||||||||||||||
Full Title: Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma | ||||||||||||||||||||||||||||
Medical condition: Progressive or refractory : • high grade glioma • neuroblastoma • other cerebral tumors • lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000896-26 | Sponsor Protocol Number: ETLAS | Start Date*: 2016-05-19 | ||||||||||||||||
Sponsor Name:Herlev Gentofte Hospital | ||||||||||||||||||
Full Title: Effect of Tadalafil on cerebral large arteries in stroke patients. | ||||||||||||||||||
Medical condition: Stroke and small vessel disease. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001579-30 | Sponsor Protocol Number: TV5600-CNS-20006 | Start Date*: 2014-11-27 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd. | |||||||||||||
Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (... | |||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005112-42 | Sponsor Protocol Number: C14-62 | Start Date*: 2015-06-22 | |||||||||||
Sponsor Name:INSERM | |||||||||||||
Full Title: A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3) | |||||||||||||
Medical condition: Huntington's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016907-41 | Sponsor Protocol Number: fMRT-Nociception | Start Date*: 2012-09-10 |
Sponsor Name:Charité, Universitätsmedizin Berlin | ||
Full Title: Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes | ||
Medical condition: This is a CT including only healthy volunteers. The aim of the study is to investigate the effect of a commonly used anesthetic drug in clinical concentrations on nociceptive and antinociceptive me... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002997-18 | Sponsor Protocol Number: 53975 | Start Date*: 2017-03-14 |
Sponsor Name:University Medical Center Utrecht, the Netherlands | ||
Full Title: Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration | ||
Medical condition: Perinatal Arterial Ischemic Stroke (PAIS) | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004974-27 | Sponsor Protocol Number: BP28015 | Start Date*: 2012-03-26 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: 89Zr-RO5323441 PET imaging in patients with recurrent glioblastoma treated with bevacizumab | |||||||||||||
Medical condition: Recurrent malignant glioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000647-30 | Sponsor Protocol Number: EFC16645 | Start Date*: 2020-08-27 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis | |||||||||||||
Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) FR (Completed) DE (Restarted) GB (GB - no longer in EU/EEA) CZ (Completed) NO (Completed) FI (Completed) DK (Completed) BE (Completed) LT (Completed) AT (Completed) GR (Completed) NL (Completed) PT (Completed) PL (Completed) HU (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019069-28 | Sponsor Protocol Number: Y-52-52120-145 | Start Date*: 2011-06-07 | |||||||||||
Sponsor Name:Ipsen Innovation | |||||||||||||
Full Title: A phase III, multicentre, prospective, double blind, randomised, placebo controlled study, assessing the efficacy and safety of Dysport intramuscular injections used for the treatment of upper limb... | |||||||||||||
Medical condition: Arm Spasticity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) SK (Completed) PL (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004890-15 | Sponsor Protocol Number: EU-C-001-II-01 | Start Date*: 2019-06-05 | |||||||||||
Sponsor Name:Eustralis Pharmaceuticals Ltd. | |||||||||||||
Full Title: A double-blind placebo-controlled study with an open-label pilot phase, assessing the efficacy, tolerability and safety of EU-C-001 in patients with moderate to severe traumatic brain injury | |||||||||||||
Medical condition: Traumatic brain injury | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
